Exact Mass: 307.2623488
Exact Mass Matches: 307.2623488
Found 133 metabolites which its exact mass value is equals to given mass value 307.2623488,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Dihydrocapsaicin
Dihydrocapsaicin is found in pepper (C. annuum). It is a potential nutriceutical. Dihydrocapsaicin is a capsaicinoid and analog and congener of capsaicin in chili peppers (Capsicum). Like capsaicin it is an irritant. Dihydrocapsaicin accounts for about 22\\\\\% of the total capsaicinoids mixture and has about the same pungency as capsaicin. Pure dihydrocapsaicin is a lipophilic colorless odorless crystalline to waxy compound. It is soluble in dimethyl sulfoxide and 100 \\\\\% ethanol. Dihydrocapsaicin is a capsaicinoid. Dihydrocapsaicin is a natural product found in Capsicum pubescens, Capsicum annuum, and Ganoderma lucidum with data available. See also: Capsicum (part of); Paprika (part of); Habanero (part of) ... View More ... Potential nutriceutical Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat[1][2][3]. Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat[1][2][3]. Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat[1][2][3].
Betaxolol
Betaxolol is only found in individuals that have used or taken this drug. It is a cardioselective beta-1-adrenergic antagonist with no partial agonist activity. [PubChem]Betaxolol selectively blocks catecholamine stimulation of beta(1)-adrenergic receptors in the heart and vascular smooth muscle. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. Betaxolol can also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles, causing bronchospasm. C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AB - Beta blocking agents, selective S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01ED - Beta blocking agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Betaxolol is a selective beta1 adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.
Amprotropine
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
Fingolimod
C19H33NO2 (307.25111580000004)
L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents > D000081243 - Sphingosine 1 Phosphate Receptor Modulators COVID info from Guide to PHARMACOLOGY, DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials C308 - Immunotherapeutic Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Pumiliotoxin A
C19H33NO2 (307.25111580000004)
Fingolimod
C19H33NO2 (307.25111580000004)
L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents > D000081243 - Sphingosine 1 Phosphate Receptor Modulators COVID info from Guide to PHARMACOLOGY, DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials C308 - Immunotherapeutic Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
N-[(4-Hydroxy-3-methoxyphenyl)methyl]-7-methylnonanamide
2-hydroxy-2-methyl-N-{trans-1-methyl-4-[(2E,4E)-6-methylhepta-2,4-dien-2-yl]cyclohexyl}-propanamide
C19H33NO2 (307.25111580000004)
2E,4E-hexadecadienoic acid isobutylamide|hexadeca-2t,4t-dienoic acid isobutylamide|Hexadeca-2t,4t-diensaeure-isobutylamid|N-isobutyl-(2E,4E)-hexadeca-2,4-dienamide|N-isobutyl-2E,4E-hexadecadienamide|N-Isobutylhexadeca-trans-2,trans-4-dienamid
octahydro-6-(4-hydroxy-2,5-dimethyl-5-octenylidene)-8-methyl-8-indolizinol
C19H33NO2 (307.25111580000004)
3-O-Tetradecanoyl-1-cyano-2-methyl-1-propene
C19H33NO2 (307.25111580000004)
18EB43C97X
n-Vanillyldecanamide is a natural product found in Capsicum annuum with data available. See also: Paprika (part of). N-Vanillyldecanamide, a capsaicinoid isolated from the fruits of Capsicum annuum, significantly reduced the radical length of Lactuca sativa seedling in a dose-dependent manner[1].
Dihydrocapsaicin
relative retention time with respect to 9-anthracene Carboxylic Acid is 1.274 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.271 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.269 Acquisition and generation of the data is financially supported in part by CREST/JST. Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat[1][2][3]. Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat[1][2][3]. Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat[1][2][3].
betaxolol
C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AB - Beta blocking agents, selective S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01ED - Beta blocking agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Betaxolol is a selective beta1 adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.
N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnonanamide
N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnonanamide [IIN-based on: CCMSLIB00000848580]
N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnonanamide [IIN-based: Match]
(8S,Z)-6-((2R,E)-4-hydroxy-2,5-dimethyloct-5-en-1-ylidene)-8-methyloctahydroindolizin-8-ol
C19H33NO2 (307.25111580000004)
(2R)-1-((8S,Z)-8-hydroxy-8-methylhexahydroindolizin-6(5H)-ylidene)-2,5-dimethyloctan-4-one
C19H33NO2 (307.25111580000004)
(7R)-8-((8S,Z)-8-hydroxy-8-methylhexahydroindolizin-6(5H)-ylidene)-4,7-dimethyloctan-3-one
C19H33NO2 (307.25111580000004)
(8S,Z)-6-((2R,E)-6-hydroxy-2,5-dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizin-8-ol
C19H33NO2 (307.25111580000004)
(8S,Z)-6-((2R,E)-7-hydroxy-2,5-dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizin-8-ol
C19H33NO2 (307.25111580000004)
(7R,8R,E)-6-((R,E)-2,5-dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizine-7,8-diol
C19H33NO2 (307.25111580000004)
FTY720
C19H33NO2 (307.25111580000004)
N-(2,6-dicyclohexyloxan-4-yl)acetamide
C19H33NO2 (307.25111580000004)
Butamirate
R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants C78273 - Agent Affecting Respiratory System > C66917 - Antitussive Agent
Levobetaxolol
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
(E)-N-propan-2-yl-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]prop-2-en-1-amine
1,7,7-trimethyl-N,N-bis(2-methylpropyl)-2-oxo-4-bicyclo[2.2.1]heptanecarboxamide
C19H33NO2 (307.25111580000004)
6-(Octahydro-1H-indol-1-ylmethyl)decahydroquinazoline-2,4-diamine
EU-0100782
Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat[1][2][3]. Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat[1][2][3]. Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat[1][2][3].
(11Z,14Z)-Icosadienoate
A polyunsaturated fatty acid anion that is the conjugate base of (11Z,14Z)-icosadienoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
Octahydro-6-(6-hydroxy-2,5-dimethyl-4-octen-1-ylidene)-8-methylindolizin-8-ol
C19H33NO2 (307.25111580000004)
(6Z,8S)-6-[(E,6S)-6-hydroxy-2,5-dimethyloct-4-enylidene]-8-methyl-1,2,3,5,7,8a-hexahydroindolizin-8-ol
C19H33NO2 (307.25111580000004)
1-(2,6-Dimethyl-4-morpholinyl)-3-(4-propan-2-ylphenoxy)-2-propanol
Perhydro-histrionicotoxin, 1,2-dedihydro-, methyl(ether)
icosadienoate
A polyunsaturated fatty acid anion that is the conjugate base of icosadienoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(8Z,11Z)-icosadienoate(1-)
An icosadienoate obtained by deprotonation of the carboxy group of (8Z,11Z)-icosadienoic acid; major species at pH 7.3.
methyl (2r)-3-[(1e)-pentadec-1-en-1-yl]-2h-azirine-2-carboxylate
C19H33NO2 (307.25111580000004)
(1r,2r,10s,11r,13s,14s,15s)-14-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadecan-11-yl acetate
(2e,4e,6e,8r)-8-hydroxy-1-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]-6-methyldodeca-2,4,6-trien-1-one
(7s)-n-[(4-hydroxy-3-methoxyphenyl)methyl]-7-methylnonanimidic acid
n-[(4-hydroxy-3-methoxyphenyl)methyl]-7-methylnonanimidic acid
4-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadecan-11-yl acetate
methyl 3-(pentadec-1-en-1-yl)-2h-azirine-2-carboxylate
C19H33NO2 (307.25111580000004)
1-ethyl-3-hydroxy-3-methyl-2-(4-methylhex-2-en-2-yl)-5-propanoyl-2h-pyridin-4-one
(2e,4e,9e,11e)-8,13-dihydroxy-n-(2-methylpropyl)tetradeca-2,4,9,11-tetraenimidic acid
3-o-tetradecanoyl-1-cyano-2-methyl-1-propene
C19H33NO2 (307.25111580000004)
{"Ingredient_id": "HBIN009382","Ingredient_name": "3-o-tetradecanoyl-1-cyano-2-methyl-1-propene","Alias": "NA","Ingredient_formula": "C19H33NO2","Ingredient_Smile": "CCCCCCCCCCCCCC(=O)OCC(=CC#N)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21026","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
5-hydroxy-2-methyl-6-(11'-oxododecyl)-pyridinen-oxide
{"Ingredient_id": "HBIN011592","Ingredient_name": "5-hydroxy-2-methyl-6-(11'-oxododecyl)-pyridinen-oxide","Alias": "NA","Ingredient_formula": "C18H29NO3","Ingredient_Smile": "CC1=[N+](C(=C(C=C1)O)CCCCCCCCCCC(=O)C)[O-]","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10510","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(6z,8s)-6-[(4e,6s)-6-hydroxy-2,5-dimethyloct-4-en-1-ylidene]-8-methyl-hexahydroindolizin-8-ol
C19H33NO2 (307.25111580000004)
n-[(4-hydroxy-3-methoxyphenyl)methyl]decanimidic acid
n-(2-hydroxy-2-methylpropyl)-12-oxotetradeca-2,4,8-trienimidic acid
(1r,2s,10s,11r,12r,13r,15r)-12-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadecan-11-yl acetate
(1s,2s,10s,11s,12s,13s,15r)-12-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadecan-11-yl acetate
5-hexyl-3-(hydroxymethyl)-decahydropyrrolo[2,1-j]quinolin-7-one
C19H33NO2 (307.25111580000004)
methyl 3-[(1z)-pentadec-1-en-1-yl]-2h-azirine-2-carboxylate
C19H33NO2 (307.25111580000004)
(2z,8z)-n-(2-oxooxolan-3-yl)tetradeca-2,8-dienimidic acid
n-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnonanimidic acid
14-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadecan-11-yl acetate
(2e,4e,6e)-8-hydroxy-1-[2-(hydroxymethyl)pyrrolidin-1-yl]-6-methyldodeca-2,4,6-trien-1-one
(2e,4e,8z)-n-(2-hydroxy-2-methylpropyl)-12-oxotetradeca-2,4,8-trienimidic acid
(6z,8s,8as)-6-[(2r,4z,6r)-6-hydroxy-2,5-dimethyloct-4-en-1-ylidene]-8-methyl-hexahydroindolizin-8-ol
C19H33NO2 (307.25111580000004)
2,6-di-tert-butyl-4-(2-methyl-2-nitropropyl)phenol
2-hydroxy-2-methyl-n-[(1r,4r)-1-methyl-4-[(2e,4e)-6-methylhepta-2,4-dien-2-yl]cyclohexyl]propanimidic acid
C19H33NO2 (307.25111580000004)
8-hydroxy-1-[2-(hydroxymethyl)pyrrolidin-1-yl]-6-methyldodeca-2,4,6-trien-1-one
(2z,7z)-n-[(3s)-2-oxooxolan-3-yl]tetradeca-2,7-dienimidic acid
12-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadecan-11-yl acetate
(3r,5s,7ar,11ar)-5-hexyl-3-(hydroxymethyl)-decahydropyrrolo[2,1-j]quinolin-7-one
C19H33NO2 (307.25111580000004)
(2s,3r,4r)-5-hydroxy-4-methyl-2-(2-methylpropyl)-3,4-dihydro-2h-pyrrol-3-yl (2e)-3-[(1s,2s)-2-propylcyclopropyl]prop-2-enoate
(3e)-1-[(2e)-5-butyl-4-hydroxy-5h-1,3-oxazol-2-ylidene]-4-methyldec-3-en-2-one
(2e,4e)-n-(2-methylpropyl)hexadeca-2,4-dienimidic acid
(1s,2r,10r,11r,13r,14r,15s)-14-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadecan-11-yl acetate
(6z,8s,8as)-6-[(2r,4e,6s)-6-hydroxy-2,5-dimethyloct-4-en-1-ylidene]-8-methyl-hexahydroindolizin-8-ol
C19H33NO2 (307.25111580000004)
(2r,3s)-1-ethyl-3-hydroxy-3-methyl-2-[(2e,4s)-4-methylhex-2-en-2-yl]-5-propanoyl-2h-pyridin-4-one
2-hydroxy-2-methyl-n-[1-methyl-4-(6-methylhepta-2,4-dien-2-yl)cyclohexyl]propanimidic acid
C19H33NO2 (307.25111580000004)